198 related articles for article (PubMed ID: 34074983)
21. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
Feagan BG; Bhayat F; Khalid M; Blake A; Travis SPL
J Crohns Colitis; 2018 Jul; 12(8):905-919. PubMed ID: 29788248
[TBL] [Abstract][Full Text] [Related]
22. Vedolizumab: first global approval.
Poole RM
Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
24. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
25. A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab.
Fukura S; Takei M; Takeuchi S; Tayama T; Ono A; Ichihara Y; Shichijo K; Suzuki Y; Mori K; Kondo S
J Med Invest; 2023; 70(1.2):294-297. PubMed ID: 37164738
[TBL] [Abstract][Full Text] [Related]
26. Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review.
Forss A; Flis P; Sotoodeh A; Kapraali M; Rosenborg S
Scand J Gastroenterol; 2024 Jul; 59(7):821-829. PubMed ID: 38682791
[TBL] [Abstract][Full Text] [Related]
27. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
28. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
29. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
30. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
31. An update on the safety of long-term vedolizumab use in inflammatory bowel disease.
Honap S; Netter P; Danese S; Peyrin-Biroulet L
Expert Opin Drug Saf; 2023; 22(9):767-776. PubMed ID: 37610086
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab-Associated Acute Respiratory Distress Syndrome.
Nambiar S; Karippot A; Oliver T
Am J Ther; 2018; 25(5):e592-e593. PubMed ID: 29189313
[No Abstract] [Full Text] [Related]
33. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
34. Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
Loftus EV; Colombel JF; Feagan BG; Vermeire S; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):400-411. PubMed ID: 27683800
[TBL] [Abstract][Full Text] [Related]
35. Severe erosive gingivostomatitis in a patient treated by vedolizumab.
Semeria L; Dadban A; Brazier F; Fumery M; Ikoli JF; Arnault JP; Adas A; Dairi M; Lok C; Chaby G
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147674
[TBL] [Abstract][Full Text] [Related]
36. Interstitial Nephritis Secondary to Vedolizumab Treatment in Crohn Disease and Safe Rechallenge Using Steroids: A Case Report.
Bailly E; Von Tokarski F; Beau-Salinas F; Picon L; Miquelestorena-Standley E; Rousseau G; Jonville-Bera AP; Halimi JM
Am J Kidney Dis; 2018 Jan; 71(1):142-145. PubMed ID: 29162338
[TBL] [Abstract][Full Text] [Related]
37. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis.
Cucinotta U; Dipasquale V; Costa S; Pellegrino S; Ramistella V; Romano C
J Clin Pharm Ther; 2022 Feb; 47(2):254-256. PubMed ID: 34278581
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
39. [Not Available].
Ravn CD; Bendix M; Lyhne S
Ugeskr Laeger; 2024 May; 186(22):. PubMed ID: 38847300
[TBL] [Abstract][Full Text] [Related]
40. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
